Morgan Stanley Maintains Overweight on IO Biotech, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on IO Biotech and raises the price target from $4 to $6.
September 16, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has increased its price target for IO Biotech from $4 to $6, maintaining an Overweight rating. This suggests a positive outlook for the company's stock.
The increase in price target from $4 to $6 by a reputable firm like Morgan Stanley indicates a positive sentiment towards IO Biotech's future performance. The Overweight rating suggests that the stock is expected to outperform its peers, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100